{"protocolSection":{"identificationModule":{"nctId":"NCT07030517","orgStudyIdInfo":{"id":"64007957MMY4007"},"secondaryIdInfos":[{"id":"64007957MMY4007","type":"OTHER","domain":"Janssen Research & Development, LLC"}],"organization":{"fullName":"Johnson & Johnson Private Limited","class":"INDUSTRY"},"briefTitle":"A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma","officialTitle":"An Open Label, Multicenter, Phase IV Study of Teclistamab to Evaluate Its Safety in Indian Participants With Relapsed and Refractory Multiple Myeloma Who Have Previously Received at Least 3 Prior Lines of Therapy Including an Immunomodulatory Agent, a Proteasome Inhibitor and an Anti-CD38 Antibody and Have Demonstrated Disease Progression on the Last Therapy"},"statusModule":{"statusVerifiedDate":"2025-06","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-05-22","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-11-03","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-06-20","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-06-12","studyFirstSubmitQcDate":"2025-06-12","studyFirstPostDateStruct":{"date":"2025-06-22","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-06-12","lastUpdatePostDateStruct":{"date":"2025-06-22","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Johnson & Johnson Private Limited","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to assess the safety of teclistamab in in routine clinical practice when given as monotherapy in Indian participants with relapsed and refractory multiple myeloma (RRMM) (that is, a blood cancer that comes back after treatment or does not respond to treatment) who have previously received at least 3 prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor and an anti-cluster of differentiation (CD)38 antibody (is a protein that fights infection) and whose disease have progressed on the last therapy."},"conditionsModule":{"conditions":["Multiple Myeloma"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":75,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Teclistamab","type":"EXPERIMENTAL","description":"Participants with RRMM eligible for receiving teclistamab will continue to receive study treatment for 6 cycles. Assessments will be done 7 days after dose 4 of 6th cycle (end of treatment \\[EOT\\]) and participants will be followed up 1 month after the EOT. Participants receiving teclistamab at the time of study completion may continue to receive teclistamab, if in the opinion of their treating physician the participants continues to derive clinical benefit from continued treatment or have not progressed clinically.","interventionNames":["Drug: Teclistamab"]}],"interventions":[{"type":"DRUG","name":"Teclistamab","description":"Teclistamab will be administered subcutaneously.","armGroupLabels":["Teclistamab"],"otherNames":["JNJ-64007957"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants with Treatment-Emergent Adverse Events (TEAE)s","description":"An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the intervention under study. TEAEs are AEs with onset during the treatment or that are a consequence of a preexisting condition that has worsened since the first dose of study treatment through the day of last dose plus 30 days or prior to the start of subsequent anticancer therapy, whichever is earlier, or any AE that is considered treatment-related regardless of the start date of the event. TEAEs reported will include all serious and non-serious adverse events.","timeFrame":"Up to approximately 7 months"}],"secondaryOutcomes":[{"measure":"Overall Response Rate (ORR)","description":"ORR is defined as the percentage of participants who have a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR) or better per investigator assessment according to the International Myeloma Working Group (IMWG) response criteria.","timeFrame":"Up to approximately 6 months"},{"measure":"Percentage of Participants With Best Response of Very Good Partial Response (VGPR) or Better","description":"VGPR or better response rate is defined as the percentage of participants who achieve a best response of VGPR or better response (sCR, CR and VGPR) as per investigator assessment according to the IMWG response criteria.","timeFrame":"Up to approximately 6 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participant diagnosed with RRMM (as per IMWG definitions or investigator's discretion) who have received at least 3 prior lines of therapy including a proteasome inhibitor, an anti-CD 38 antibody and an immunomodulatory agent and have demonstrated disease progression on the last therapy\n* Documented evidence of progressive measurable disease on last line of therapy at screening based on investigator's determination of response by IMWG diagnostic criteria\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\n* Contraceptive use by female participants should be consistent with local regulations. A female participant is eligible to participate if she is not pregnant or breastfeeding, and not a woman of child bearing potential (WOCBP) or is a WOCBP and using a contraceptive method that is highly effective\n* A WOCBP must have a negative highly sensitive serum pregnancy test within 24 hours before the first dose of study treatment\n\nExclusion Criteria:\n\n* Participants who are not eligible to receive teclistamab as per the locally approved prescribing information\n* Received any prior B cell maturation antigen (BCMA)-directed therapy\n* Central nervous system (CNS) involvement or clinical signs of meningeal involvement of multiple myeloma\n* Stroke, transient ischemic attack, or seizure within 6 months prior to screening\n* Participant had major surgery or had significant traumatic injury within 2 weeks prior to enrollment, or will not have fully recovered from surgery, or has major surgery planned during the time the participant is expected to be treated in the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Study Contact","role":"CONTACT","phone":"844-434-4210","email":"Participate-In-This-Study1@its.jnj.com"}],"overallOfficials":[{"name":"Johnson & Johnson Private Limited Clinical Trial","affiliation":"Johnson & Johnson Private Limited","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Bhagwan Mahaveer Cancer Hospital & Research Centre","status":"RECRUITING","city":"Jaipur","zip":"302017","country":"India","geoPoint":{"lat":26.91962,"lon":75.78781}},{"facility":"Tata Medical Center","status":"RECRUITING","city":"Kolkata","zip":"700156","country":"India","geoPoint":{"lat":22.56263,"lon":88.36304}},{"facility":"KIMS-Kingsway Hospitals","status":"RECRUITING","city":"Nagpur","zip":"440001","country":"India","geoPoint":{"lat":21.14631,"lon":79.08491}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \\& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.","url":"https://www.janssen.com/clinical-trials/transparency"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-07-07"},"conditionBrowseModule":{"meshes":[{"id":"D009101","term":"Multiple Myeloma"},{"id":"D054219","term":"Neoplasms, Plasma Cell"}],"ancestors":[{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"},{"id":"D020141","term":"Hemostatic Disorders"},{"id":"D014652","term":"Vascular Diseases"},{"id":"D002318","term":"Cardiovascular Diseases"},{"id":"D010265","term":"Paraproteinemias"},{"id":"D001796","term":"Blood Protein Disorders"},{"id":"D006402","term":"Hematologic Diseases"},{"id":"D006474","term":"Hemorrhagic Disorders"},{"id":"D008232","term":"Lymphoproliferative Disorders"},{"id":"D007160","term":"Immunoproliferative Disorders"},{"id":"D007154","term":"Immune System Diseases"}],"browseLeaves":[{"id":"M12058","name":"Multiple Myeloma","asFound":"Multiple Myeloma","relevance":"HIGH"},{"id":"M27588","name":"Neoplasms, Plasma Cell","asFound":"Multiple Myeloma","relevance":"HIGH"},{"id":"M20559","name":"Disease Progression","relevance":"LOW"},{"id":"M12315","name":"Neoplasms by Histologic Type","relevance":"LOW"},{"id":"M21977","name":"Hemostatic Disorders","relevance":"LOW"},{"id":"M5059","name":"Blood Coagulation Disorders","relevance":"LOW"},{"id":"M17400","name":"Vascular Diseases","relevance":"LOW"},{"id":"M13178","name":"Paraproteinemias","relevance":"LOW"},{"id":"M5077","name":"Blood Protein Disorders","relevance":"LOW"},{"id":"M9490","name":"Hematologic Diseases","relevance":"LOW"},{"id":"M9560","name":"Hemorrhagic Disorders","relevance":"LOW"},{"id":"M11225","name":"Lymphoproliferative Disorders","relevance":"LOW"},{"id":"M10206","name":"Immunoproliferative Disorders","relevance":"LOW"},{"id":"M10200","name":"Immune System Diseases","relevance":"LOW"},{"id":"T3947","name":"Multiple Myeloma","asFound":"Multiple Myeloma","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"BC15","name":"Blood and Lymph Conditions"},{"abbrev":"BC20","name":"Immune System Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M2853","name":"Immunomodulating Agents","relevance":"LOW"},{"id":"M4225","name":"Antibodies","relevance":"LOW"},{"id":"M10184","name":"Immunoglobulins","relevance":"LOW"},{"id":"M29889","name":"Proteasome Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}